The renewable energy battery developer, an MIT spinout, raised funding that will be used to expand its manufacturing capabilities.
University of Oxford’s genetic therapeutics spinout has secured the crossover funding eight months after a series A round also backed by OSI.
Osage University Partners has backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.
A range of strategic investors have backed a series A5 round for the clean nuclear energy technology developer that leverages OSU research.
Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.
UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.
PsiQuantum has become the first unicorn in Imec.xpand’s portfolio as it fetched a valuation of more than $3bn.
IP Group is among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.